Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY7.74 CNY
Change Today -0.05 / -0.64%
Volume 24.4M
600713 On Other Exchanges
Symbol
Exchange
Shanghai
As of 3:05 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

nanjing pharmaceutical co-a (600713) Snapshot

Open
CNY7.45
Previous Close
CNY7.79
Day High
CNY8.25
Day Low
CNY7.30
52 Week High
06/3/15 - CNY20.50
52 Week Low
09/17/14 - CNY6.72
Market Cap
6.9B
Average Volume 10 Days
23.2M
EPS TTM
CNY0.22
Shares Outstanding
897.4M
EX-Date
04/9/14
P/E TM
34.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for NANJING PHARMACEUTICAL CO-A (600713)

Related News

No related news articles were found.

nanjing pharmaceutical co-a (600713) Related Businessweek News

No Related Businessweek News Found

nanjing pharmaceutical co-a (600713) Details

Nanjing Pharmaceutical Company Limited manufactures and distributes Chinese medicines and western drugs in China. It is involved in the pharmaceutical distribution operations, which include operation of regular chain drug stores, delivery of pharmaceuticals, supply chain management, logistics services, and others; and pharmaceutical production operations providing Chinese patent medicines, tablets, capsules, granules, solvents, bulk drugs, and others. The company is also engaged in the asset management business, which includes credit guarantee and international trading, as well as provides hotel and information services. Nanjing Pharmaceutical Co., Ltd. was founded in 1951 and is based in Nanjing, the People’s Republic of China.

Founded in 1951

nanjing pharmaceutical co-a (600713) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nanjing pharmaceutical co-a (600713) Key Developments

Nanjing Pharmaceutical Company Limited Reports Financial Results for the First Half of 2015

NanJing Pharmaceutical Company Limited reported financial results for the first half of 2015. For the period, the company reported basic earnings per share of CNY 0.090 and weighted average return on net assets of 3.69%.

NanJing Pharmaceutical Company Limited to Amend Articles of Association

NanJing Pharmaceutical Company Limited directorate decided to hold a special Shareholders' Meeting by way of combination of on-the-spot and online voting on September 16, 2015 to discuss a proposal of amending some clauses in the Articles of Association.

NanJing Pharmaceutical Company Limited, Board Meeting, Aug 27, 2015

NanJing Pharmaceutical Company Limited, Board Meeting, Aug 27, 2015. Agenda: To discuss and approve the proposal of supplementing director of the seventh directorate, the semi-annual report of 2015 and its abstract; and to consider the proposal of providing guarantee for bank loan of some subsidiaries.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600713:CH CNY7.74 CNY -0.05

600713 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Huadong Medicine Co Ltd CNY70.97 CNY -3.55
Jointown Pharmaceutical Group Co Ltd CNY19.12 CNY +0.78
Shanghai Pharmaceuticals Holding Co Ltd CNY19.05 CNY +0.30
Wanjia Group Holdings Ltd $0.52 HKD +0.03
View Industry Companies
 

Industry Analysis

600713

Industry Average

Valuation 600713 Industry Range
Price/Earnings 41.7x
Price/Sales 0.3x
Price/Book 3.0x
Price/Cash Flow 36.9x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANJING PHARMACEUTICAL CO-A, please visit www.njyy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.